跳轉至內容
Merck
全部照片(1)

重要文件

300116S

Avanti

Control (5mL vial)

Avanti Research - A Croda Brand

同義詞:

Control (Pegylated Liposomal Vehicle), frozen liposomal suspension (buffer - 10% w/w sucrose, 10 mM histidine ~pH 6.5)

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352211
NACRES:
NA.25

化驗

>99% (HPLC/MS)

形狀

solution

包裝

pkg of 1 × 5 mL (300116S-1EA)

製造商/商標名

Avanti Research - A Croda Brand

應用

vaccine development

運輸包裝

dry ice

儲存溫度

−20°C

一般說明

Formulation: A Pegylated, long-circulating liposomal formulation with an ammonium sulfate core. Liposomes are stored frozen for a longer shelf life.

應用

Control (5mL vial) has been used as a control for doxorubicin Hcl product (Dox2) to study its characteristics by asymmetrical-flow field flow fractionation (MD-AF4). It may be used as a vehicle control liposome for liposomal encapsulated doxorubicin (Dox-NP).

包裝

10 mL clear serum vial (300116S-1EA)

法律資訊

Avanti Research is a trademark of Avanti Polar Lipids, LLC

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Physical characterization of liposomal drug formulations using multi-detector asymmetrical-flow field flow fractionation
Parot J, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society (2020)
J Parot et al.
Journal of controlled release : official journal of the Controlled Release Society, 320, 495-510 (2020-02-01)
Liposomal formulations for the treatment of cancer and other diseases are the most common form of nanotechnology enabled pharmaceuticals (NEPs) submitted for market approval and in clinical application today. The accurate characterization of their physical-chemical properties is a key requirement;

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務